Adenosine News and Research RSS Feed - Adenosine News and Research

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a ß-N9-glycosidic bond.
Single enzyme doing the work of a trio could offer precise way to treat diseases

Single enzyme doing the work of a trio could offer precise way to treat diseases

Researchers identified a single enzyme doing the work of a trio thought necessary to control a common cellular signaling process being pursued as a therapeutic target. [More]
Researchers investigate effects of non-allergenic components of pollen on allergy sufferers

Researchers investigate effects of non-allergenic components of pollen on allergy sufferers

Up to now, research into pollen allergies has largely focused on allergens - those components of pollen that trigger hypersensitivity reactions. When it comes into contact with the nasal mucous membrane, however, pollen releases a host of other substances in addition to allergens. [More]
Rapamycin drug could target neural damage linked to Leigh syndrome

Rapamycin drug could target neural damage linked to Leigh syndrome

Salk Institute scientists showed how an FDA-approved drug boosts the health of brain cells by limiting their energy use. Like removing unnecessary lighting from a financially strapped household to save on electricity bills, the drug--called rapamycin--prolongs the survival of diseased neurons by forcing them to reduce protein production to conserve cellular energy. [More]
African sleeping sickness parasite has defence mechanism against potential pharmaceuticals

African sleeping sickness parasite has defence mechanism against potential pharmaceuticals

Researchers from Umea University in Sweden have discovered that the single-celled parasite causing African sleeping sickness has a defence mechanism against potential pharmaceuticals under development against the disease. The deadly parasite has an enzyme that can cleave and hence disarm adenosine analogue pharmaceuticals. This according to a study recently published in the Journal of Biological Chemistry. [More]
Cornell researchers discover potential way to penetrate blood brain barrier

Cornell researchers discover potential way to penetrate blood brain barrier

Cornell researchers have discovered a way to penetrate the blood brain barrier (BBB) that may soon permit delivery of drugs directly into the brain to treat disorders such as Alzheimer's disease and chemotherapy-resistant cancers. [More]
Researchers identify vital inflammatory mechanisms in type 1 diabetes, obesity-related kidney dysfunction

Researchers identify vital inflammatory mechanisms in type 1 diabetes, obesity-related kidney dysfunction

In a new study, published in the online edition of the journal EBioMedicine, a multi-disciplinary team led by researchers at University of California, San Diego School of Medicine has identified key inflammatory mechanisms underlying type 1 diabetes and obesity-related kidney dysfunction. [More]
Manipulation of NAD could lead to potential therapy for acute kidney injury

Manipulation of NAD could lead to potential therapy for acute kidney injury

Approximately one out of five hospitalized adults and one out of three hospitalized children worldwide experience acute kidney injury, the sudden loss of kidney function. Many different factors, including surgery, chemotherapy or shock, can lead to acute kidney injury, but exactly why the kidneys are so vulnerable to these and other stressors has not been well understood. [More]
Discovery may provide potential target for new therapies to treat bipolar disorder

Discovery may provide potential target for new therapies to treat bipolar disorder

Bipolar disorder, which affects nearly eight million Americans, takes a toll not only on patients, but also on their families and communities. [More]
Polyunsaturated lipids can alter binding rate of two receptors involved in Parkinson's and Alzheimer's

Polyunsaturated lipids can alter binding rate of two receptors involved in Parkinson's and Alzheimer's

A study published in the prestigious journal Scientific Reports from the Nature group demonstrates, for the first time and using computational tools, that polyunsaturated lipids can alter the binding rate of two types of receivers involved in certain nervous system diseases. [More]
Study shows new RNA letter as regulatory key to control gene expression

Study shows new RNA letter as regulatory key to control gene expression

DNA, RNA, protein -- the end. Or is it? Until recently, the pattern used to encode genetic information into our cells was considered to be relatively straightforward: four letters (A,G,C,T) for DNA and four (A,G,C,U) for RNA. This equation, however, turned out to be oversimplified -- RNA was holding out. [More]
Research: Adenosine deaminase may help activate immune system against HIV

Research: Adenosine deaminase may help activate immune system against HIV

New research findings published in the February 2016 issue of the Journal of Leukocyte Biology, suggest that a new therapeutic strategy for HIV may already be available by repurposing an existing prescription drug. [More]
Researchers reveal specific enzyme responsible for sensing energy source that fuels growth of cancer cells

Researchers reveal specific enzyme responsible for sensing energy source that fuels growth of cancer cells

An international research team formed by a University of Cincinnati cancer researcher has shown for the first time that a specific enzyme is responsible for sensing the available supply of GTP, an energy source that fuels the uncontrolled growth of cancer cells. The research underscores the enzyme's potential to become a therapeutic target for future cancer drugs. [More]
Antiscarring paste can halt fibrosis caused by radiation treatment

Antiscarring paste can halt fibrosis caused by radiation treatment

An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy. That is according to a study led by researchers at Laura and Isaac Perlmutter Cancer Center to be published tomorrow in the January edition of the Journal of the Federation of American Societies for Experimental Biology, or FASEB. [More]
Study on myosins may lead to therapies for muscle diseases, cancers

Study on myosins may lead to therapies for muscle diseases, cancers

Understanding how tiny molecular motors called myosins use energy to fuel biological tasks like contracting muscles could lead to therapies for muscle diseases and cancers, says a team of researchers led by Penn State College of Medicine scientists. [More]
Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Cancer, it could be said, grows like a weed: rapidly, invasively, and with devastating impact on the place it infests. Also like a weed, cancer can't grow on its own — it needs nourishment, which it drains from the human body, just as weeds take nutrients in the soil away from other plants. [More]
New technique could improve heart scans for patients

New technique could improve heart scans for patients

A team of Oxford University researchers has developed a technique that could improve heart scans for patients, giving more information about the heart than traditional scans and without any injections, making them safer and faster. [More]
Tetra begins human Phase 1 safety trials of BPN14770

Tetra begins human Phase 1 safety trials of BPN14770

Tetra Discovery Partners today announced that the company has initiated human Phase 1 safety trials of its lead compound BPN14770, which Tetra is developing as a potential treatment to both improve memory and slow the progression of Alzheimer's disease. [More]
Scientists reveal why loss of CD73 enzyme in human cancer promotes tumor progression

Scientists reveal why loss of CD73 enzyme in human cancer promotes tumor progression

Scientists have shown for the first time why loss of the enzyme CD73 in human cancer promotes tumor progression. [More]
OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

OphthaliX Inc., a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd., announced today that it has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma. [More]
New hope for patients with Duchenne muscular dystrophy

New hope for patients with Duchenne muscular dystrophy

New hope for Duchenne muscular dystrophy (DMD) patients. A mouse genetic study in PLoS Medicine reports that targeting the P2RX7 gene, a purinoreceptor, may halt the progression of DMD. [More]
Advertisement
Advertisement